A Single-Arm, Open-Label, Expanded Access Study of RO5185426 in Patients With Metastatic Melanoma (Genentech #ML25597)
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Expanded access
- Sponsors Roche
- 15 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Apr 2011 Planned end date added (Mar 2013) as reported by ClinicalTrials.gov.